I had this thought at first too, but there's a more granular breakdown: 74% healthcare, of which 34% are IT, 28% are diagnostics, 24% are therapeutics, 14% are

I had this thought at first too, but there's a more granular breakdown: 74% healthcare, of which 34% are IT, 28% are diagnostics, 24% are therapeutics, 14% are devices. Using that info, taking what I consider the most reasonable strict approach (exclude IT, diagnostics, and devices), you'd exclude ~64% of the defined companies. Without a complete listing of the companies considered, it's hard to gauge how strict you'd need to be in order to be precise, but since the point of this post is to highlight that bio and hard tech companies are being actively funded by YC and have been for a while now, I think the author's assumptions were pretty reasonable.